Health-related quality of life in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors and immunotherapy: An observational study (PROmRCC study)
Not Applicable
Recruiting
- Conditions
- Renal cell carcinoma
- Registration Number
- JPRN-UMIN000040922
- Lead Sponsor
- Hirosaki University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria were mRCC patients (1) who had the IMDC favorable-risk disease, (2) who were not able to answer QoL questionnaire, and (3) who were not feasible for immunotherapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method